ouraring.com

Oura, the Finnish-American company whose $299 Oura Ring 5 tracks heart rate, temperature, respiratory rate, sleep, and blood oxygen from a wearer's finger, is acquiring AI-native primary care company Counsel Health for $625 million in cash, the company announced Monday. The deal, expected to close before December 31, 2026, pending customary regulatory approvals, marks the largest acquisition in Oura's history and signals an aggressive pivot from wearable hardware into physician-mediated clinical care.

Oura reported $533 million in revenue for the period ending September 30, 2026 — up 153 percent year over year — with the full fiscal year 2026 on track to reach approximately $1.75 billion, representing 92 percent annual growth. Dr. Muthu Alagappan, Counsel's founder and CEO, will join Oura as its chief clinical AI officer; Counsel's 70 employees will transfer to Oura as part of the deal. Tom Hale, Oura's CEO, said in the company's announcement: "Oura's record growth of 153 percent this quarter and our over six million members provides us the confidence to invest $625 million cash to acquire Counsel Health. Wearable data has earned a place at the clinical table. This acquisition puts a physician at that table alongside it."

How the Technology Works

The acquisition formalizes and expands a pipeline that Oura has been building in stages. Oura's Ring 5 collects continuous biometric streams — sleep stage architecture, blood oxygen saturation (SpO2), heart rate variability, and skin temperature deviation — using photoplethysmography (PPG) optical sensors embedded in the ring's inner face. Those streams travel via Bluetooth Low Energy to the Oura mobile app, then to Oura's cloud infrastructure over connections encrypted at TLS 1.2 or higher.

Under the Counsel integration, members who consent to sharing their data trigger a second pipeline: a FHIR-based API transmits a structured biometric summary to Counsel Health's HIPAA-compliant clinical system, where an AI model surfaces the most clinically relevant patterns before a physician reads the chart. The result is that a Counsel physician enters the first patient message already holding weeks or months of objective physiological data — not a self-reported symptom list.

One regulatory distinction matters for members: the consumer Oura Ring, used without the Counsel integration, is not classified as a medical device and is not covered by the Health Insurance Portability and Accountability Act (HIPAA). It falls instead under the FDA's General Wellness Policy for low-risk devices. The Counsel integration changes that for enrolled members: once a member opts in and their data crosses into Counsel's clinical environment, that data is handled under HIPAA-equivalent protections with SOC 2 Type II certification.

Early Evidence From the Partnership

Counsel Health and Oura have been operating as integration partners since June 2026. The service went live in June 2026 when Counsel rolled out through Oura Labs — Oura's beta channel for new features — to eligible members in 43 states, with a nationwide rollout contingent on the acquisition closing. In the first 90 days following the June launch, more than 36,000 Oura members enrolled in the Counsel service, and internal satisfaction surveys showed that more than 70 percent of users rated the experience "very satisfied."

The service carries a $159 annual subscription fee, separate from the cost of the Oura Ring hardware and the standard Oura membership. Of that annual fee, the $76.50 to Counsel Medical Group flows directly to the licensed physician entity that employs or contracts with the network's doctors, with the remainder allocated to Oura for data infrastructure, scheduling technology, and platform margin.

Why $625 Million — and Why Now

The timing of the deal cannot be separated from Oura's recent financial trajectory. Oura filed its S-1 registration statement with the Securities and Exchange Commission on September 3, targeting a valuation of up to $2.2 billion in a planned initial public offering. On September 29, citing "uncertainty in the IPO market," Oura postponed the offering indefinitely — a decision that left the company sitting on substantial cash reserves while its IPO window remained closed.

The Counsel acquisition deploys that capital into a vertical expansion rather than a financial return event. It also follows a pattern Oura established in April 2026, when it acquired Galen AI, a Y Combinator-backed health data integration startup from the YC Spring 2025 batch that had been building the data infrastructure layer connecting wearable streams to clinical workflows. The Galen AI acquisition gave Oura the technical foundation on which the Counsel integration was built; the Counsel acquisition adds the licensed physician network on top of it.

The CMS Connection

Counsel Health's participation in the CMS ACCESS Model is a significant structural feature of the acquisition. The CMS Advancing Chronic Care with Effective, Scalable Solutions (ACCESS) Model is a 10-year voluntary Medicare payment program that launched July 1, 2026 and rewards providers for measurable improvements in patient health outcomes rather than the volume of services rendered. Under the program's Outcome-Aligned Payment (OAP) framework, Counsel's physician network earns enhanced reimbursement when patients demonstrate quantifiable improvements in chronic condition markers — blood pressure, blood glucose stability, weight, and sleep quality among them.

The significance for Oura is structural: by acquiring Counsel, Oura's revenue is now partially tied to whether its biometric data actually produces better patient health outcomes, not merely whether members purchase subscriptions. If a Counsel physician uses Oura's data to identify an undiagnosed sleep apnea pattern that leads to a treated and stable patient, that outcome generates additional reimbursement under the ACCESS framework. The incentive structure aligns Oura's financial interest with the clinical result in a way that a pure subscription model does not.

Addressing the Physician Shortage

The acquisition positions Oura inside a healthcare access problem that continues to widen. The Association of American Medical Colleges projects a physician shortage of 86,000 by 2036 — the upper bound of a range that starts at 13,500 — driven by an aging population requiring more complex care and a physician workforce aging into retirement. Grand View Research projects the global telemedicine segment to approach $299 billion by 2028 as providers and payers respond to the access gap.

Dr. Alagappan holds a BS in Biomechanical Engineering and an MD from Stanford University and has practiced as an attending physician at Massachusetts General Hospital and UCSF Medical Center. He was formerly chief medical officer at Notable Health, an AI-driven clinical workflow company. At Oura, he will oversee the clinical AI strategy across the combined platform, including the development of AI models trained on Oura's longitudinal biometric dataset.

The core argument of the Counsel integration is that a physician who already holds six months of a patient's sleep, cardiovascular, and temperature data before the first appointment can practice more efficiently and more accurately than one working from a blank chart. In the context of a physician shortage, that efficiency multiplier matters: a clinician who can triage patients by objective physiological urgency rather than self-reported symptom severity can serve more patients, with better-calibrated attention, in the same amount of time.

Privacy and Data Considerations

The integration raises ongoing questions about the boundary between consumer wellness products and regulated medical infrastructure. Consumer wearable data — including data from the Oura Ring — does not currently carry HIPAA protections by default. Senator Bill Cassidy introduced the Health Information Privacy Reform Act in 2025 to extend HIPAA-equivalent protections to wearable health data at the federal level; that legislation advanced out of the Senate HELP Committee on a 22-0 vote in August 2026 but remains pending a full Senate vote.

In a December 2025 Wall Street Journal op-ed, Hale called on the FDA and Congress to create a third regulatory classification — "digital health screeners" — for wearables that sit between the FDA's current General Wellness category and full medical device regulation. The FDA responded by issuing a revised General Wellness Policy in January 2026 that expanded the categories of wearable metrics eligible for the lower-risk classification, effectively broadening the zone in which companies like Oura operate without medical device approval requirements. Representative Troy Balderson (R-Ohio), who chairs the House digital health caucus, is working on legislation to formalize the screener classification that Hale advocated for.

Oura's Washington lobbying efforts have expanded alongside its regulatory ambitions. In October 2026, Oura signed a data-sharing partnership with Palantir for de-identified population health analytics — a deal that drew scrutiny from privacy advocates who noted that Palantir's existing government contracts create a path, however indirect, between consumer wellness data and federal health agencies. Oura said the Palantir partnership involves fully de-identified data with no individual-level linkage possible.

What It Means for Oura Members

The practical implications of the acquisition for existing Oura members break down into several immediate and near-term changes.

Who is eligible: All Oura Ring members in the 43 states currently served by Counsel Health are eligible to enroll immediately. Members in the remaining seven states and U.S. territories will gain access as Counsel's physician network expands, which Oura expects to complete by mid-2027.

What the service includes: Enrolled members receive asynchronous messaging access to a Counsel physician who has reviewed their Oura biometric history before the first contact. The service is intended for primary care questions, preventive health consultations, and chronic condition monitoring — not emergency care or specialist referrals, though physicians can facilitate referrals.

What it costs: The $159 annual fee is charged separately from any hardware purchase or existing Oura membership subscription. Members who enrolled during the Oura Labs beta period are grandfathered at their original rate through the end of their current enrollment period.

Data and privacy: Members who do not opt into the Counsel integration retain the same data handling as before — Oura's existing privacy policy applies, and no biometric data is transferred to Counsel's clinical system without explicit member consent. Members who do opt in can withdraw consent and request data deletion from Counsel's system at any time.

How to access it: The Counsel integration is currently accessible through the Oura app under the Health tab. A redesigned Care experience is expected to roll out as a primary navigation tab by Q1 2027, with an expanded provider directory and direct booking capabilities.

Looking Ahead

The acquisition places Oura in direct competition with an emerging set of companies pursuing the same clinical integration strategy. WHOOP, Oura's closest direct competitor in the premium biometric wearable space, raised $575 million at a $10.1 billion valuation in March 2026 and has announced partnerships with health systems and insurance networks, though it has not yet moved to acquire a physician entity directly. The two companies are converging on the same strategic destination — wearable biometric data as clinical infrastructure — through different capital and partnership structures.

Oura's decision to acquire rather than partner reflects both its cash position after the IPO postponement and a judgment that ownership of the physician layer, rather than a commercial arrangement with it, is the more defensible competitive position. A partnership can be renegotiated or dissolved; a 70-person physician network is part of the company's permanent clinical architecture.

The IPO question remains open. Hale declined to comment on a revised IPO timeline in Monday's announcement, saying only that the company would "evaluate public market conditions as they develop." The Counsel acquisition signals that Oura does not intend to wait passively for the IPO window to reopen: it is deploying capital to build the kind of healthcare infrastructure that, if the clinical outcomes data supports it, could command a materially higher valuation than the $2.2 billion ceiling the September S-1 targeted.

"The question is no longer whether wearables belong in healthcare," Hale said in Monday's announcement. "The question is whether the data you collect can produce better health outcomes. That is what we have set out to prove."